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Introduction: Breast cancer in situ (BCIS) diagnoses, a precursor lesion for invasive breast cancer, comprise about
20 % of all breast cancers (BC) in countries with screening programs. Family history of BC is considered one of the
strongest risk factors for BCIS.
Methods: To evaluate the association of BC susceptibility loci with BCIS risk, we genotyped 39 single nucleotide
polymorphisms (SNPs), associated with risk of invasive BC, in 1317 BCIS cases, 10,645 invasive BC cases, and 14,006
healthy controls in the National Cancer Institute’s Breast and Prostate Cancer Cohort Consortium (BPC3). Using
unconditional logistic regression models adjusted for age and study, we estimated the association of SNPs with
BCIS using two different comparison groups: healthy controls and invasive BC subjects to investigate whether BCIS
and BC share a common genetic profile.
Results: We found that five SNPs (CDKN2BAS-rs1011970, FGFR2-rs3750817, FGFR2-rs2981582, TNRC9-rs3803662,
5p12-rs10941679) were significantly associated with BCIS risk (P value adjusted for multiple comparisons <0.0016).
Comparing invasive BC and BCIS, the largest difference was for CDKN2BAS-rs1011970, which showed a positive
association with BCIS (OR = 1.24, 95 % CI: 1.11–1.38, P = 1.27 x 10−4) and no association with invasive BC (OR = 1.03,
95 % CI: 0.99–1.07, P = 0.06), with a P value for case-case comparison of 0.006. Subgroup analyses investigating
associations with ductal carcinoma in situ (DCIS) found similar associations, albeit less significant (OR = 1.25,
95 % CI: 1.09–1.42, P = 1.07 x 10−3). Additional risk analyses showed significant associations with invasive
disease at the 0.05 level for 28 of the alleles and the OR estimates were consistent with those reported by
other studies.
Conclusions: Our study adds to the knowledge that several of the known BC susceptibility loci are risk
factors for both BCIS and invasive BC, with the possible exception of rs1011970, a putatively functional SNP
situated in the CDKN2BAS gene that may be a specific BCIS susceptibility locus.* Correspondence: r.kaaks@dkfz.de
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Breast cancer in situ (BCIS) is a preinvasive breast can-
cer (BC) with the potential to transform into an invasive
tumor within a time period that could vary between a
few years to decades [1]. Only a subset of BCIS evolves
into the invasive stage, and not all invasive cancers arise
from BCIS [2–4]. Which factors influence the progres-
sion of BCIS to invasive BC is still unclear [2, 5, 6]. BCIS
was rarely diagnosed before mass screening for BC, but
since the introduction of screening they comprise about
20 % of all diagnosed BC [7, 8].
Ductal carcinoma in situ (DCIS) is the most common
form of noninvasive BC. It is characterized by malignant
epithelial cells inside the milk ducts of the breast. DCIS
is known to be a different entity from lobular carcinoma
in situ (LCIS), which is characterized by proliferation of
malignant cells in the lobules of the breast [9] and is
more frequently associated to lobular invasive BC than
to ductal invasive BC. DCIS is generally considered a
precursor lesion of invasive BC; however, a direct causal-
ity has not been firmly established because it is not
possible to verify that the removal of DCIS decreases the
risk of developing the invasive disease [3, 10].
BCIS is largely understudied and its etiology is poorly
understood compared to invasive BC. Family history of
BC is considered one of the strongest risk factors
[11, 12], clearly stressing the importance of the genetic
background. However, only a small number of studies have
investigated the genetic risk factors specific for BCIS
[13, 14] or DCIS [15, 16]. Genome-wide association studies
(GWAS) including both invasive and BCIS cases tend to
find similar associations between the two diseases but no
specific loci have been identified for BCIS [17–19]. Find-
ings from the Million Women Study indicated that 2p-
rs4666451 may be differentially associated with invasive
BC and BCIS [13], while Milne and colleagues identified
the association of 5p12-rs10941679 with lower-grade BC
as well as with DCIS, but not with high-grade BC [15].
With the aim of verifying whether susceptibility SNPs
identified through GWAS on invasive BC are also rele-
vant for BCIS, we selected 39 single nucleotide polymor-
phisms (SNPs) previously shown to be associated with
invasive BC, and performed an association study on
1317 BCIS cases and 14,006 controls in the context of
the US National Cancer Institute’s Breast and Prostate
Cancer Cohort Consortium (BPC3). In addition, we
compared the association in BCIS with 10,645 invasive
BC cases to investigate whether the two types of disease
share a common genetic profile or not.
Methods
Study population
The National Cancer Institute’s Breast and Prostate
Cancer Cohort Consortium (BPC3) has been describedextensively elsewhere [20]. Briefly, it consists of large,
well-established cohorts assembled in Europe, Australia
and the United States that have both DNA samples and
extensive questionnaire information collected at base-
line. Cases were women who had been diagnosed with
BCIS or invasive BC after enrolment in one of the BPC3
cohorts. This study included 10,645 invasive BC cases,
1317 BCIS cases and 14,006 controls. Of the 1317 BCIS
cases included in this study, 71 % had information on
tumor histology. Out of these, 85 % had DCIS and 15 %
had LCIS. Controls were healthy women selected from
each cohort. Relevant institutional review boards from
each cohort approved the project and informed consent
was obtained from all participants. The names of all
approving Institutional Review Boards can be found in
the Acknowledgements section.
SNP selection and genotyping
The SNPs included in this analysis were reported to
show a statistically significant association with invasive
BC risk (P <5 × 10−7) in at least one published study.
For eight SNPs whose assays did not work satisfactorily
we selected a surrogate in complete linkage disequilib-
rium (r2 = 1 in HapMap Caucasian in Europe (CEU)). In
particular, for the following SNPs we have genotyped
either the original SNP or the surrogate: rs4415084
(surrogate rs920329), rs9344191 (surrogate rs9449341),
rs1250003 (surrogate rs704010), rs999737 (surrogate
rs10483813), rs2284378 (surrogates rs8119937 and
rs6059651), rs2180341 (surrogate rs9398840), rs311499
(surrogate rs311498,) and rs1917063 (surrogate rs9344208).
Genotyping was performed using TaqMan assays
(Applied Biosystems, Foster City, CA, USA), as specified
by the producer. Genotyping of the cases and controls
was performed in four laboratories (the German Cancer
Research Center (DKFZ), the University of Southern
California, the US National Cancer Institute (NCI), and
Harvard School of Public Health). Additional informa-
tion on the genotyping techniques is given elsewhere
[21]. Laboratory personnel were blinded to whether the
subjects were cases or controls. Duplicate samples
(approximately 8 %) were also included.
Data filtering and statistical analysis
Concordance of the duplicate samples was evaluated and
found to be greater than 99.99 % for each SNP. Each
SNP was tested for Hardy-Weinberg equilibrium in the
controls by study. We investigated the association be-
tween genetic variants and BCIS risk by fitting an un-
conditional logistic regression model, adjusted for age at
recruitment and cohort (defined as study phase in NHS).
Since there were only 19 BCIS patients in the European
Prospective Investigation into Cancer (EPIC) we did not
adjust the BCIS risk models for country. Instead, we
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notypes were treated as nominal variables, comparing
heterozygotes and minor allele homozygotes to the
reference group major allele homozygotes. For the
same reason, we did not adjust the risk models for
ethnicity but performed sensitivity analyses excluding
non-Caucasians.
To test if there were differences in the genetic suscep-
tibility for the two diseases, we performed case-case ana-
lyses and subgroup analyses, matching distinct controls
to BCIS cases and invasive cases, respectively. The
matching factors were age at baseline, menopausal status
at baseline and cohort. The same type of case-case ana-
lyses were carried out comparing allele distributions
between invasive BC and DCIS cases. Furthermore, we
investigated the specific associations of the alleles with
DCIS.
The significance threshold was adjusted, taking into
account the large number of tests carried out. Since
some of the SNPs map to the same regions and might
be in linkage disequilibrium, for each locus we calculated
the effective number of independent SNPs, the number
of effectively independent variables (Meff ), using the
SNP Spectral Decomposition approach (simpleM method)
(13). The study-wise Meff obtained was 31 and the adjusted
threshold for significance was 0.05/(31) = 0.0016. All statis-
tical tests were two-sided and all statistical analyses were
performed with SAS software version 9.2 (SAS Institute,
Inc., Cary, NC, USA).
Bioinformatic analysis
We used several bioinformatic tools to assess possible
functional relevance for the SNP-BCIS associations.
RegulomeDB [22] and HaploReg v2B [23] were used to
identify the regulatory potential of the region nearby the
SNP. The GENe Expression VARiation database (Genevar)
[24] was used to identify potential associations between the
SNP and expression levels of nearby genes expression
quantitative trait loci (eQTL).
Results
In this study, we investigated the possible effect of 39
SNPs associated with invasive BC on the susceptibility of
BCIS using 1317 BCIS cases and 14,006 healthy controls
in the framework of BPC3. The relevant characteristics
of the study population are presented in Table 1. The
vast majority (69 %) of the study participants were post-
menopausal and of European ancestry.
We removed subjects from the NHS cohort for the
analysis of ZMIZ1-rs1045485 and 11q13-rs614367
since the genotype distribution showed departure from
the Hardy-Weinberg equilibrium among the controls
(P = 8.4 × 10−4 and P = 6 × 10−4, respectively) in
this cohort. All other SNPs were in Hardy-Weinbergequilibrium (P >0.05). The results of the sensitivity analyses
showed that the exclusion of EPIC and non-Caucasian sub-
jects did not affect the results (data not shown).
SNP associations comparing BCIS with controls
We found significant associations (at the conven-
tional 0.05 level) between 14 SNPs and risk of BCIS,
with P values ranging from 0.041 (GMBE2-rs311499)
to 3.0 x 10−6 (FGFR2-rs2981582) (Table 2). When ac-
counting for multiple testing (P <0.0016), five SNPs
(CDKN2BAS-rs1011970, FGFR2-rs3750817, FGFR2-
rs2981582, TNRC9-rs3803662, 5p12-rs10941679) showed
a statistically significant association with BCIS. Another
variant (ZNF365-rs10995190) was very close to this sig-
nificance threshold (P = 0.0019). None of the SNPs asso-
ciated exclusively with estrogen receptor negative (ER-)
BC (C19Orf62-rs8170, RALY-rs2284378, USHBP1-
rs12982178 and TERT-rs10069690) or with both ER-
and estrogen receptor positive (ER+) (6q14-rs13437553,
6q14-rs9344191, 6q14-rs17530068 and 20q11-rs4911414)
in the literature showed an association with BCIS in this
study, even at the 0.05 level.
SNP associations comparing DCIS with controls
By utilizing information on tumor histology we selected
the DCIS cases and investigated the associations between
the alleles and risk. Of the five SNPs significantly associ-
ated with BCIS, two (CDKN2BAS-rs1011970, TNRC9-
rs3803662) showed a statistically significant association
with DCIS (Table S1 in Additional file 1).
SNP associations comparing BCIS with invasive BC
Using case-case analyses to explore possible heterogen-
eity of associations of the SNPs with the risk of BCIS
compared to invasive BC, we found no significant differ-
ences in the distribution of the genotypes of the selected
SNPs by outcome (Table 3). The strongest difference
was observed for CDKN2BAS-rs1011970, although it
was not statistically significant considering multiple test-
ing (P value for case-case comparison = 0.006), suggest-
ing a stronger association of CDKN2BAS-rs1011970
with BCIS than with invasive BC. We also performed a
subgroup analysis (BCIS vs. invasive) using matched
controls in order to more clearly observe the direction
of the associations between the selected SNPs and the
risk of the two diseases. These latter analyses confirmed
that CDKN2BAS-rs1011970 had a preferential associ-
ation with BCIS compared to invasive BC, however, in
both cases the minor T allele was associated with in-
creased risk (Table S2 in Additional file 2).
When comparing invasive BC to DCIS, we ob-
served that CDKN2BAS-rs1011970 showed the most
promising, albeit nonsignificant association (P value
for DCIS vs. BC case-case comparison = 0.0206, Table S3
Table 1 Characteristics of the study subjects (BCIS and controls)
CPS-II EPIC MEC NHS PLCO Total
Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases
Number 3048 569 4745 19 1724 74 3630 489 859 166 14,006 1317
Ductal 297 (52 %) 14 (74 %) 367 (75 %) 114 (69 %) 792 (62 %)
Lobular 42 (8 %) 2 (10 %) 82 (17 %) 15 (9 %) 141 (11 %)
Unknown/other 230 (40 %) 3 (16 %) 74 (100 %) 40 (8 %) 37 (22 %) 384 (29 %)
White 3048 569 4745 19 574 15 3605 467 859 166 12,831 1236
Hispanic . . . . 292 10 2 . . . 294 10
African American . . . . 230 9 7 11 . . 237 20
Asian . . . . 379 23 7 6 . . 386 29
Hawaiian . . . . 249 17 . . . . 249 17
Other . . . . . . 9 5 . . 9 5
Age at diagnosis/recruitment, mean (sd) 61.9 (6.2) 68.81 (6.87) 54.0 (8.0) 61.16 (7.32) 57.0 (8.4) 62.86 (8.00) 57.1 (10.7) 59.04 (10.2) 62.3 (5.0) 66.13 (5.54) 57.4 (8.9) 64.41 (9.31)
ER positive . 151 . 4 . 10 . 175 . 32 . 372
ER negative . 22 . . . 2 . 35 . 9 . 68
ER not classified . 396 . 15 . 58 . 26 . . . 495
ER not classified . . . . . 4 . 253 . 125 . 382
BMI (kg/m2), mean (sd) 25.60 (4.93) 25.50 (4.82) 25.44 (4.31) 23.47 (3.57) 26.85 (6.16) 27.54 (5.68) 25.85 (5.20) 25.61 (5.12) 27.08 (5.38) 27.76 (5.47) 25.90 (5.05) 25.91 (5.12)
Height (m), mean (sd) 1.64 (0.063) 1.64 (0.065) 1.62 (0.066) 1.61 (0.054) 1.61 (0.070) 1.59 (0.069) 1.64 (0.061) 1.64 (0.064) 1.63 (0.063) 1.63 (0.067) 1.63 (0.066) 1.64 (0.066)
Premenopausal 108 34 1134 3 357 14 1046 172 . . 2645 223
Postmenopausal 2902 527 2883 13 1307 56 2473 305 852 165 10,417 1066
Perimenopausal 38 8 728 3 60 4 111 12 7 1 944 28
CPS-II Cancer Prevention Study II, EPIC European Prospective Investigation into Cancer, MEC Multiethnic Cohort, NHS Nurses’ Health Study, PLCO Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, sd standard deviation,













Table 2 Association between the selected SNPs and risk of developing breast cancer in situ
SNP Gene Allelesa Cases Controls OR (95 % CI) Ptrend Reference
MM Mm mmb MM Mm mmb
rs11249433 NOTCH2 T G 412 588 228 4757 5523 1892 1.10 (1.01-1.20) 0.022993 [34, 35]
rs10931936 CASP8 G T 595 479 82 5705 4499 840 0.99 (0.90-1.09) 0.876814 [36]
rs1045485 CASP8 G G 629 163 15 6653 1839 133 0.94 (0.80-1.11) 0.481823 [37]
rs13387042 Intergenic A G 369 590 258 3452 5942 2847 0.88 (0.81-0.96) 0.004138 [18]
rs4973768 SLC4A7 G T 300 617 307 3482 6000 2728 1.07 (0.98-1.17) 0.11062 [38]
rs4415084c Intergenic G T 384 620 218 4133 5847 2217 1.11 (1.01-1.21) 0.023783 [19]
rs10941679 Intergenic A G 610 478 88 6626 4601 854 1.18 (1.07-1.30) 0.001069 [19]
rs10069690 TERT G T 665 467 87 6199 4136 774 1.03 (0.93-1.13) 0.573721 [39]
rs889312 MAP3K1 A G 603 506 130 6113 5020 1135 1.16 (1.06-1.27) 0.001841 [17]
rs17530068 Intergenic T G 727 425 86 6642 4137 648 1.01 (0.91-1.11) 0.879429 [35]
rs13437553 Intergenic T G 340 181 41 4628 2761 414 1.00 (0.86-1.15) 0.953341 [35]
rs1917063d Intergenic G T 741 424 74 6933 3949 571 1.03 (0.94-1.14) 0.502161 [35]
rs9344191e Intergenic T G 680 447 100 6365 4280 735 1.04 (0.95-1.15) 0.40587 [35]
rs2180341f RNF146 A G 685 458 81 6395 4084 650 1.06 (0.96-1.17) 0.250858 [40]
rs3757318 Intergenic G A 1019 197 8 9641 1631 54 1.19 (1.02-1.39) 0.02862 [26]
rs9383938 Intergenic G T 1013 212 12 9530 1820 85 1.13 (0.97-1.30) 0.108581 [35, 41]
rs2046210 Intergenic G T 501 565 163 5216 5494 1535 1.09 (0.99-1.19) 0.071176 [42, 43]
rs13281615 Intergenic A G 419 582 210 4068 5818 2232 1.00 (0.92-1.10) 0.915006 [38]
rs1562430 Intergenic T G 419 595 222 3821 5594 2023 1.00 (0.92-1.09) 0.992865 [26]
rs1011970 CDKN2BAS G T 793 396 42 7977 3099 319 1.24 (1.11-1.38) 0.000127 [44]
rs865686 Intergenic T G 481 599 157 4511 5257 1673 0.96 (0.88-1.04) 0.328473 [44]
rs2380205 Intergenic G T 402 597 239 3502 5637 2272 0.98 (0.90-1.06) 0.579359 [44]
rs10995190 ZNF365 G A 943 277 18 8224 2923 238 0.82 (0.72-0.93) 0.001998 [44, 45]
rs16917302 ZNF365 A G 1006 220 12 9313 2041 102 1.01 (0.88-1.17) 0.849328 [45, 46]
rs1250003g ZMIZ1 A G 444 567 227 4369 5309 1742 1.13 (1.04-1.24) 0.004096 [44, 47]
rs3750817 FGFR2 G T 503 552 178 3989 5362 1804 0.86 (0.79-0.94) 0.00101 [48]
rs2981582 FGFR2 G T 385 608 241 4591 5793 1847 1.23 (1.13-1.34) 0.00000283 [38]
rs3817198 LSP1 T G 550 540 138 5807 5185 1178 1.03 (0.94-1.13) 0.467045 [17]
rs909116 LSP1 T G 357 608 269 3125 5656 2640 0.96 (0.88-1.04) 0.309715 [26]
rs614367 Intergenic G T 548 188 19 5783 1909 186 1.04 (0.89-1.21) 0.63419 [49]
rs999737h RAD51L1 G T 751 418 58 6575 3927 656 0.89 (0.80-0.99) 0.025235 [34]
rs3803662 TNRC9 G T 572 514 116 6132 4896 1070 1.20 (1.09-1.32) 0.00015 [17, 18]
rs2075555 COL1A1 G A 939 265 13 8348 2582 211 0.88 (0.77-1.01) 0.062916 [50]
rs6504950 COX11 G A 653 499 85 6586 4772 911 0.96 (0.88-1.06) 0.444627 [38]
rs12982178 USHBP1 T G 790 391 58 7458 3649 476 1.02 (0.92-1.14) 0.667534 [35]
rs8170 C19Orf62 G A 816 372 50 7699 3446 420 1.02 (0.91-1.13) 0.736771 [35]
rs2284378i RALY G T 504 455 107 4955 4625 1079 0.95 (0.86-1.05) 0.298392 [35]
rs4911414 Intergenic G T 549 545 135 5083 5000 1295 0.95 (0.87-1.04) 0.26966 [35]
rs311499j GMEB2 G T 1049 169 14 9878 1491 68 1.17 (1.00-1.37) 0.04566
SNP single nucleotide polymorphism, OR, odds ratio, CI confidence interval
aThe first allele is the major, the second is the minor allele
bM = Major allele; m = minor allele
c5p12-rs4415084 or surrogate 5p12-rs920329
d6q14-rs1917063 or surrogate 6q14-rs9344208
e6q14-rs9344191 or surrogate 6q14-rs9449341
fECHDC1R, NF146-rs2180341 or surrogate ECHDC1R, NF146-rs9398840
gZMIZ1-rs1250003 or surrogate ZMIZ1-rs704010
hRAD51L1-rs999737 or surrogate RAD51L1-rs10483813
iRALY-rs2284378 or surrogate RALY-rs6059651, RALY-rs8119937
jGMEB2-rs311499 or surrogate GMEB2-rs311498
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Table 3 Case-case analysis between invasive breast cancer and breast cancer in situ
SNP Gene Allelesa Invasive breast cancer Breast cancer in situ OR (95 % CI) Ptrend
MM Mm mmb MM Mm mmb
rs11249433 NOTCH2 T G 2569 3884 1474 412 588 228 1.03 (0.94-1.13) 4,87E-01
rs10931936 CASP8 G T 4470 3697 775 595 479 82 1.06 (0.96-1.18) 2,50E-01
rs1045485 CASP8 G G 4570 1293 102 629 163 15 1.09 (0.92-1.28) 3,23E-01
rs13387042 Intergenic A G 2432 3707 1750 369 590 258 0.95 (0.88-1.04) 2,96E-01
rs4973768 SLC4A7 G T 1976 4013 1932 300 617 307 0.97 (0.89-1.06) 4,86E-01
rs4415084c Intergenic G T 2559 3863 1437 384 620 218 0.99 (0.91-1.08) 8,66E-01
rs10941679 Intergenic A G 4193 3143 605 610 478 88 0.99 (0.89-1.09) 8,19E-01
rs10069690 TERT G T 4243 3076 549 665 467 87 1.01 (0.91-1.11) 9,01E-01
rs889312 MAP3K1 A G 3848 3306 729 603 506 130 0.96 (0.87-1.06) 4,01E-01
rs17530068 Intergenic T G 5171 3453 582 727 425 86 1.05 (0.95-1.17) 3,16E-01
rs13437553 Intergenic T G 3582 2288 361 340 181 41 1.05 (0.90-1.22) 5,60E-01
rs1917063d Intergenic G T 5433 3301 497 741 424 74 1.02 (0.92-1.13) 7,26E-01
rs9344191e Intergenic T G 4972 3566 645 680 447 100 1.01 (0.92-1.12) 8,36E-01
rs2180341f RNF146 A G 4623 2823 479 685 458 81 0.94 (0.85-1.04) 2,35E-01
rs3757318 Intergenic G A 7679 1443 66 1019 197 8 1.01 (0.86-1.18) 9,46E-01
rs9383938 Intergenic G T 7563 1568 104 1013 212 12 1.01 (0.87-1.17) 8,87E-01
rs2046210 Intergenic G T 3207 3633 1069 501 565 163 1.00 (0.91-1.10) 9,69E-01
rs13281615 Intergenic A G 2544 3773 1455 419 582 210 1.07 (0.98-1.17) 1,46E-01
rs1562430 Intergenic T G 3392 4347 1496 419 595 222 0.93 (0.85-1.02) 1,12E-01
rs1011970 CDKN2BAS G T 6327 2623 258 793 396 42 0.85 (0.76-0.96) 6,50E-03
rs865686 Intergenic T G 3847 4247 1125 481 599 157 0.93 (0.85-1.02) 1,47E-01
rs2380205 Intergenic G T 2961 4505 1742 402 597 239 0.99 (0.91-1.08) 8,03E-01
rs10995190 ZNF365 G A 6818 2172 172 943 277 18 1.07 (0.94-1.22) 3,28E-01
rs16917302 ZNF365 A G 7599 1574 86 1006 220 12 0.97 (0.84-1.13) 7,02E-01
rs1250003g ZMIZ1 A G 3395 4394 1432 444 567 227 0.93 (0.85-1.02) 1,20E-01
rs3750817 FGFR2 G T 3146 3615 1063 503 552 178 1.01 (0.92-1.10) 8,82E-01
rs2981582 FGFR2 G T 2469 3868 1546 385 608 241 1.00 (0.91-1.09) 9,66E-01
rs3817198 LSP1 T G 3657 3387 821 550 540 138 0.97 (0.88-1.06) 4,67E-01
rs909116 LSP1 T G 2610 4586 2040 357 608 269 1.02 (0.94-1.12) 6,31E-01
rs614367 Intergenic G T 5119 1937 226 548 188 19 1.14 (0.98-1.33) 9,15E-02
rs999737h RAD51L1 G T 4829 2702 401 751 418 58 1.04 (0.93-1.15) 5,22E-01
rs3803662 TNRC9 G T 3655 3328 797 572 514 116 1.02 (0.92-1.12) 7,25E-01
rs2075555 COL1A1 G A 5851 1856 165 939 265 13 1.18 (1.03-1.35) 1,41E-02
rs6504950 COX11 G A 4296 3104 547 653 499 85 0.97 (0.88-1.07) 5,34E-01
rs12982178 USHBP1 T G 6028 2990 327 790 391 58 0.95 (0.86-1.06) 4,04E-01
rs8170 C19Orf62 G A 6237 2816 290 816 372 50 0.96 (0.85-1.07) 4,36E-01
rs2284378i RALY G T 4080 3624 899 504 455 107 1.01 (0.92-1.12) 7,95E-01
rs4911414 Intergenic G T 4177 3954 1048 549 545 135 1.02 (0.93-1.11) 7,34E-01
rs311499j GMEB2 G T 7987 1162 66 1049 169 14 0.87 (0.74-1.03) 1,03E-01
SNP single nucleotide polymorphism, OR, odds ratio, CI confidence interval
aThe first allele is the major, the second is the minor allele
bM = Major allele; m = minor allele
c5p12-rs4415084 or surrogate 5p12-rs920329
d6q14-rs1917063 or surrogate 6q14-rs9344208
e6q14-rs9344191 or surrogate 6q14-rs9449341
fECHDC1R, NF146-rs2180341 or surrogate ECHDC1R, NF146-rs9398840
gZMIZ1-rs1250003 or surrogate ZMIZ1-rs704010
hRAD51L1-rs999737 or surrogate RAD51L1-rs10483813
iRALY-rs2284378 or surrogate RALY-rs6059651, RALY-rs8119937
jGMEB2-rs311499 or surrogate GMEB2-rs311498
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ciation of CDKN2BAS-rs1011970 with DCIS compared
to invasive BC in the subgroup analyses (Table S4 in
Additional file 4).
Additionally we also performed an association study
considering only invasive BC and we found signifi-
cant associations at the conventional 0.05 for 28 loci
(P values ranging from 0.0387 to 2.27 × 10–16)
(Table S2 in Additional file 2).
Possible functional effects
For CDKN2BAS-rs1011970, HaploReg showed that the
G to T nucleotide change of the SNP may alter the bind-
ing site for three transcription factors: FOXO4, TFC12
and p300. The Regulome DB had no data for this SNP
and Genevar showed that the T allele is associated with
decreased CDKN2BA gene expression (P = 0.002).
Discussion
With the aim of better understanding the relationship of
the genetic background with BCIS, we analyzed the as-
sociations of 39 previously identified BC susceptibility
SNPs with BCIS risk compared to normal controls and
invasive BC cases. Our general observation, as noted by
others [13, 16], is that BCIS and invasive BC seem to
share the same genetic risk factors. This is also sup-
ported by the fact that for the five alleles that were sig-
nificantly associated (P <0.0016) with BCIS risk the odds
ratio (OR) for BCIS risk was on the same side of 1 as
the OR for invasive disease. This was true also for all the
14 alleles that were nominally (P <0.05) associated with
BCIS risk with the exception of GMEB2-rs311499. How-
ever, none of the established ER- specific BC susceptibil-
ity loci were associated with BCIS risk in our study. This
is not surprising because it is likely that most of the
BCIS cases in our study might be ER+ (the information
on this variable is extremely sparse in BPC3) and sug-
gests that, from a genetic point of view, ER+ and
ER- tumors have different risk factors even for the
first stages of carcinogenesis. However, it is difficult
to draw a definitive conclusion without more complete ER
status data in BPC3.
When conducting case-case analysis, we observed a
difference in the association of CDKN2BAS-rs1011970
with invasive BC and BCIS, suggesting an association
with BCIS only, although this difference was not statisti-
cally significant after adjusting for multiple comparisons
(P = 0.006). The association between rs1011970 and BC
risk (OR = 1.20) was reported by Turnbull using a large
GWAS conducted in European studies and was repli-
cated in the Breast Cancer Association Consortium
(BCAC; OR = 1.09) [25, 26]. The lack of association be-
tween this SNP and risk of invasive BC in our study does
not appear to be due to a lack of statistical power, sincewith 10,645 invasive BC cases and 14,006 controls we
had more than 80 % power to detect an OR of 1.1 or
greater, while the ORs reported by Turnbull for this
polymorphism ranged from 1.19 to 1.45, depending on
the type of statistical model used. However, the results
reported by Turnbull originate from cases with a family
history of invasive BC, which might explain the contra-
dictory results. These could also arise due to differing
adjustments in the statistical models, different screening
programs or ways of diagnosing BCIS, or by chance.
Additionally, the results from Turnbull and colleagues
arise from a case-control study while ours are from a
prospective cohort and it has been observed that there
might be discrepancies between the two study designs [27].
We found significant associations at the conventional 0.05
level with invasive BC risk for 28 of the loci. For all of these
SNPs, the directions of the associations were consistent
with those reported in the literature [25, 28].
From a biological point of view the association be-
tween rs1011970 and BCIS is intriguing since the SNP
lies on 9p21, in an intron of the CDKN2B antisense
(CDKN2B-AS1) gene, whose sequence overlaps with that
of CDKN2B and flanks CDKN2A. These two genes
encode cyclin-dependent kinase inhibitors and are fre-
quently mutated, deleted or hypermethylated in several
cancer types, including BC [29–32].
HaploReg showed that the G to T nucleotide change of
rs1011970 altered the binding ability of three important
cell cycle regulators (FOXO4, TFC12 and p300), possibly
altering CDKN2B regulation. This hypothesis is corrobo-
rated by Genevar, which showed that the T allele was asso-
ciated with a decreased gene expression. These data are
consistent with the observation of an increased BC risk
associated with the minor allele. The CDKN2B gene regu-
lates cell growth and inhibits cell cycle G1 progression.
The malfunctioning of this checkpoint might be particu-
larly important in the initiation of the tumor. CDKN2B
has been repeatedly found to be hypermethylated – a sign
that the gene has been shut down, in benign lesions of the
breast and in BCIS [30, 31], indicating its involvement in
the early phases of carcinogenesis. Furthermore, Worsham
and colleagues found that CDKN2B was crucial for initiat-
ing immortalization events but less important for progres-
sion to malignancy [33]. Taken together, these results
suggest an involvement of the gene in early BC carcino-
genesis and are consistent with our findings that the
association of the SNP with BC overall could be due
to its association with development of early-stage tu-
mors, including BCIS, through the downregulation of
the CDKN2B gene.
A limitation of this report is the fact that since the
study focuses on the 39 SNPs associated with risk of
invasive BC, there may be other SNPs specific for BCIS
that could not be identified with this approach.
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In conclusion, our findings further support that the
genetic variants associated with risk of BCIS and inva-
sive BC largely overlap, with the possible exception of
rs1011970, a putatively functionally relevant SNP situ-
ated in the CDKN2BAS gene that may be a specific BCIS
locus. The discovery of a specific locus for BCIS may
improve our understanding on both invasive and nonin-
vasive BC susceptibility. However, our results for
rs1011970 do not meet the criteria of statistical signifi-
cance imposed by the number of tests and therefore
could still reflect a chance finding.Additional files
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